Clinical Trial Update: A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN [Phase 3]

View source ↗

Summary

Phase 3 trial comparing MRG003 to Cetuximab/Methotrexate in recurrent/metastatic squamous cell carcinoma of the head and neck is ongoing with status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Cetuximab (cetuximab)
• METHOTREXATE (METHOTREXATE)
• MRG003

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Status: UNKNOWN